(Q45870073)

English

Safety and pharmacokinetics of a glycoPEGylated recombinant activated factor VII derivative: a randomized first human dose trial in healthy subjects

scientific article published in July 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/21575130

Safety and pharmacokinetics of a glycoPEGylated recombinant activated factor VII derivative: a randomized first human dose trial in healthy subjects (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/21575130

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

J Møss

1

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/21575130

A Rosholm

2

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/21575130

A Laurén

3

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/21575130

publication date

1 July 2011

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/21575130

Journal of Thrombosis and Haemostasis

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/21575130

9

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/21575130

7

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/21575130

1368-1374

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/21575130

Paediatric haemophilia with inhibitors: existing management options, treatment gaps and unmet needs

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04344.X

21 January 2018

Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04344.X

21 January 2018

Immune tolerance induction in hemophilia A: a review

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04344.X

21 January 2018

Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic procedures

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04344.X

21 January 2018

Prophylactic recombinant factor VIIa in haemophilia patients with inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04344.X

21 January 2018

Immune tolerance induction with mycophenolate-mofetil in two children with haemophilia B and inhibitor

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04344.X

21 January 2018

Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04344.X

21 January 2018

Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04344.X

21 January 2018

Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04344.X

21 January 2018

A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25 degrees C stable formulation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04344.X

21 January 2018

Overview of the human pharmacokinetics of recombinant activated factor VII.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04344.X

21 January 2018

Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04344.X

21 January 2018

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04344.X

21 January 2018

PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04344.X

21 January 2018

Comparison of coagulant activity of factor VII and activated factor VII activity assays when used for determination of recombinant activated factor VII levels in plasma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04344.X

21 January 2018

Blood coagulation: hemostasis and thrombin regulation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2011.04344.X

21 January 2018

Identifiers

10.1111/J.1538-7836.2011.04344.X

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/21575130

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/21575130

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45870073&oldid=2156983697"